|
|
| | STAT3-IN-12 Basic information |
| Product Name: | STAT3-IN-12 | | Synonyms: | STAT3-IN-12;2,6-Bis(3-methoxyphenyl)-1,7-dipropyl-1,7-dihydrobenzo[1,2-d:4,5-d']diimidazole;2,6-Bis(3-methoxyphenyl)-1,7-dipropyl-1,7-dihydrobenzo[1,2-d:4,5-d']diimidazole | | CAS: | 2980758-31-2 | | MF: | C28H30N4O2 | | MW: | 454.56 | | EINECS: | | | Product Categories: | | | Mol File: | 2980758-31-2.mol |  |
| | STAT3-IN-12 Chemical Properties |
| Boiling point | 675.6±65.0 °C(predicted) | | density | 1.19±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 4.12±0.50(predicted) | | form | Solid | | color | Off-white to light yellow |
| | STAT3-IN-12 Usage And Synthesis |
| Uses | STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma[1]. | | in vivo | STAT3-IN-12 (compound 24, intraperitoneal injection, 20, 40 mg/kg, daily for 24 days) displays obvious antitumor activity in a mouse HepG2 cell xenograft tumor model without no obvious toxicity[1].
| Animal Model: | HepG2 cell xenograft tumor model[1] | | Dosage: | 20, 40 mg/kg, daily for 24 days | | Administration: | Intraperitoneal injection | | Result: | Inhibited tumor growth without affecting the body weight. |
| | IC 50 | STAT3 | | References | [1] Yi-Chen Liu, et al. Benzobis(imidazole) derivatives as STAT3 signal inhibitors with antitumor activity. DOI:10.1016/j.bmc.2022.116757 |
| | STAT3-IN-12 Preparation Products And Raw materials |
|